Market Capitalization (Millions $) |
55 |
Shares
Outstanding (Millions) |
34 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-67 |
Cash Flow (TTM) (Millions $) |
-113 |
Capital Exp. (TTM) (Millions $) |
1 |
Reneo Pharmaceuticals Inc
Reneo Pharmaceuticals Inc is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of therapies for patients with rare, genetic diseases. The company's focus is primarily on mitochondrial diseases, which are a group of genetic disorders that affect the way cells produce energy. These diseases are caused by mutations in genes that result in defects in the function of the mitochondria, which are organelles responsible for energy production. The consequences of these mutations can be severe, leading to a wide range of symptoms and complications.
The company was founded in 2015 and is headquartered in San Diego, California. Reneo Pharmaceuticals' management team has a strong track record in the development of therapeutics for mitochondrial diseases. The company has a team of experienced industry professionals who are passionate about the development of therapies for patients with rare diseases.
Reneo's lead product candidate, REN001, is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that is being developed as a potential treatment for primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). REN001 has received orphan drug designation from the US Food and Drug Administration (FDA) for both indications, and the company is currently conducting clinical trials to assess its safety and efficacy. The trials are expected to be completed by the end of 202
Reneo Pharmaceuticals' pipeline also includes other potential treatments for mitochondrial diseases, including a second-generation PPARd agonist and a mitochondria-targeted compound. The company is committed to developing novel therapies for patients with rare, genetic diseases and is working to advance the science of mitochondrial biology to improve the lives of those affected by these conditions.
Company Address: 18575 Jamboree Road, Suite 275-S Irvine 92612 CA
Company Phone Number: 283-0280 Stock Exchange / Ticker: NASDAQ RPHM
RPHM is expected to report next financial results on March 26, 2024. |
|
|